NOVATO, Calif., December 29, 2025 — Ultragenyx Pharmaceutical announced results from its Phase 3 Orbit and Cosmic clinical trials evaluating setrusumab (UX143) in patients with osteogenesis imperfecta (OI), a rare genetic bone disorder. The company reported that neither study met its primary endpoint of reducing annualized clinical fracture rate, compared with placebo or bisphosphonates, respectively. However, both trials achieved their key secondary endpoints, demonstrating statistically significant improvements in bone mineral density (BMD) with no new safety concerns, prompting further data analyses to determine next steps for the program.

Science Significance

From a scientific standpoint, the Phase 3 data provide important insight into the biological effects of sclerostin inhibition in OI. Setrusumab is a fully human monoclonal antibody that blocks sclerostin, a negative regulator of bone formation, with the goal of increasing bone mass and strength. The consistent and robust BMD improvements observed across both Orbit and Cosmic studies, aligned with earlier Phase 2 findings, confirm target engagement and biological activity. However, the disconnect between improved bone density and fracture reduction highlights the complex pathophysiology of OI, where bone quality, structure, and mechanical properties may not be fully captured by density measures alone.

Regulatory Significance

Regulatorily, the results represent a mixed late-stage outcome that will require careful interpretation. While failure to meet primary endpoints complicates traditional approval pathways, the presence of strong secondary endpoint data, a clean safety profile, and prior orphan-focused development provides context for ongoing regulatory discussions. Rare disease regulators often consider the totality of evidence, including biomarker and imaging endpoints, particularly in conditions with no globally approved therapies. Ultragenyx’s decision to conduct additional analyses suggests continued engagement with regulators to assess whether specific subpopulations, alternative endpoints, or future study designs may support a viable regulatory strategy.

Business Significance

For Ultragenyx, the announcement has immediate portfolio and financial implications. The company indicated it will implement significant expense reductions while reassessing the future of the setrusumab program. Despite this setback, Ultragenyx continues to generate commercial revenue from multiple approved products and is preparing for other late-stage milestones, underscoring its broader operational resilience. The results also inform capital allocation decisions, emphasizing the importance of data-driven portfolio prioritization in rare disease biopharma.

Patients’ Significance

For patients and families affected by OI, the findings are disappointing but not without significance. OI is associated with frequent fractures, pain, reduced mobility, and lifelong disability, and treatment options remain limited. The meaningful BMD gains observed, particularly in pediatric patients with higher baseline fracture risk, suggest that setrusumab may still hold potential clinical relevance that warrants deeper exploration. While fracture reduction remains the most critical outcome, improvements in bone density may contribute to long-term skeletal health, especially during childhood growth.

Policy Significance

At the policy level, the trials underscore the challenges of evaluating therapies for rare genetic diseases using conventional clinical endpoints. OI exemplifies conditions where adaptive trial designs, surrogate markers, and long-term outcome measures may be necessary to fully assess therapeutic benefit. The results reinforce the need for continued regulatory flexibility, orphan disease incentives, and sustained investment to ensure innovation does not stall following complex or inconclusive late-stage data.

In conclusion, Ultragenyx’s Phase 3 Orbit and Cosmic results for setrusumab deliver a nuanced clinical picture, combining clear biological activity and safety with primary endpoint limitations. As the company undertakes further analyses to define the future of the program, the data will inform not only strategic decisions for setrusumab but also broader approaches to clinical development in rare bone diseases. For stakeholders across science, regulation, and patient advocacy, the findings highlight both the promise and the complexity of advancing novel therapies in osteogenesis imperfecta.

Source:  Ultragenyx Pharmaceutical Inc. press release